DK1609853T4 - Fremgangsmåde til kontrol med sialylering af proteiner produceret af pattedyrscellekultur - Google Patents

Fremgangsmåde til kontrol med sialylering af proteiner produceret af pattedyrscellekultur Download PDF

Info

Publication number
DK1609853T4
DK1609853T4 DK05017434.1T DK05017434T DK1609853T4 DK 1609853 T4 DK1609853 T4 DK 1609853T4 DK 05017434 T DK05017434 T DK 05017434T DK 1609853 T4 DK1609853 T4 DK 1609853T4
Authority
DK
Denmark
Prior art keywords
sialylation
control
cell culture
mammalian cell
proteins produced
Prior art date
Application number
DK05017434.1T
Other languages
Danish (da)
English (en)
Other versions
DK1609853T3 (da
Inventor
Werner Lesslauer
Wolfgang Richter
Thomas Ryll
Thomas Schreitmüller
Tina Etcheverry
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23863440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1609853(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1609853T3 publication Critical patent/DK1609853T3/da
Publication of DK1609853T4 publication Critical patent/DK1609853T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05017434.1T 1995-06-06 1996-06-06 Fremgangsmåde til kontrol med sialylering af proteiner produceret af pattedyrscellekultur DK1609853T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,348 US5705364A (en) 1995-06-06 1995-06-06 Mammalian cell culture process
PCT/US1996/009284 WO1996039488A1 (en) 1995-06-06 1996-06-06 Process for controlling sialylation of proteins produced by mammalian cell culture

Publications (2)

Publication Number Publication Date
DK1609853T3 DK1609853T3 (da) 2009-06-02
DK1609853T4 true DK1609853T4 (da) 2020-04-06

Family

ID=23863440

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05017434.1T DK1609853T4 (da) 1995-06-06 1996-06-06 Fremgangsmåde til kontrol med sialylering af proteiner produceret af pattedyrscellekultur
DK96918251T DK0832189T4 (da) 1995-06-06 1996-06-06 Fremgangsmåde til regulering af sialylering af proteiner produceret af en pattedyrcellekultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96918251T DK0832189T4 (da) 1995-06-06 1996-06-06 Fremgangsmåde til regulering af sialylering af proteiner produceret af en pattedyrcellekultur

Country Status (35)

Country Link
US (1) US5705364A (enExample)
EP (2) EP0832189B2 (enExample)
JP (2) JPH11507523A (enExample)
KR (1) KR100496356B1 (enExample)
CN (1) CN1166772C (enExample)
AR (2) AR004940A1 (enExample)
AT (2) ATE425245T2 (enExample)
AU (1) AU717847B2 (enExample)
BG (1) BG63213B1 (enExample)
BR (1) BR9609150A (enExample)
CA (1) CA2220684C (enExample)
CZ (1) CZ293719B6 (enExample)
DE (2) DE69637867D1 (enExample)
DK (2) DK1609853T4 (enExample)
EA (1) EA001215B1 (enExample)
ES (2) ES2248812T5 (enExample)
GE (1) GEP20012519B (enExample)
HU (1) HU226420B1 (enExample)
IL (1) IL122398A (enExample)
IS (1) IS2614B (enExample)
MY (1) MY113496A (enExample)
NO (1) NO322276B1 (enExample)
NZ (1) NZ310202A (enExample)
OA (1) OA10753A (enExample)
PL (1) PL185484B1 (enExample)
PT (1) PT1609853E (enExample)
RO (1) RO120267B1 (enExample)
SA (1) SA96170351B1 (enExample)
SI (2) SI1609853T2 (enExample)
SK (1) SK282658B6 (enExample)
TR (1) TR199701543T1 (enExample)
TW (2) TW516962B (enExample)
UA (1) UA47428C2 (enExample)
WO (1) WO1996039488A1 (enExample)
ZA (1) ZA964776B (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
TR199802238T2 (xx) * 1996-05-08 1999-02-22 F. Hoffmann-La Roche Ag Astımın TNFR-Ig ile tedavisi.
DK1036179T4 (da) * 1997-12-03 2014-03-31 Roche Diagnostics Gmbh Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering
US6140445A (en) * 1998-04-17 2000-10-31 Crompton Corporation Silane functional oligomer
ATE314485T1 (de) * 1998-05-29 2006-01-15 Genentech Inc Zellkulturverfahren für die produktion von glycoproteinen
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
GB9828624D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Production of proteins
KR100475417B1 (ko) * 1998-12-30 2005-07-18 씨제이 주식회사 시알산 함량이 높은 재조합 당단백질의 제조방법
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
KR100394474B1 (ko) * 1999-12-18 2003-08-09 동아제약 주식회사 동물세포에서 재조합 당단백질의 연속식 대량생산 방법
DE60116137T2 (de) * 2000-05-16 2006-08-24 Lipoxen Technologies Ltd. Derivatisierung von proteinen in wässrigem lösungsmittel
US20030170813A1 (en) * 2000-07-05 2003-09-11 Kenichi Suga Process for producing glycoprotein
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AU2002316230A1 (en) * 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
MXPA04009381A (es) 2002-03-27 2005-01-25 Immunex Corp Metodos para incrementar la produccion de polipeptidos.
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
MXPA05005921A (es) * 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
JP2007525176A (ja) * 2003-04-25 2007-09-06 イミュネックス・コーポレーション 組換えタンパク質発現の誘導剤
EP2298898B1 (en) 2003-10-24 2012-12-26 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
AU2004309114A1 (en) * 2003-12-23 2005-07-14 Laboratoires Serono Sa Process for the production of tumor necrosis factor-binding proteins
EP1709185A1 (en) * 2003-12-31 2006-10-11 Samyang Genex Corporation Method for mass production of secondary metabolites in plant cell culture by treatment of an alkanoic acid or salt thereof
AU2005215889B9 (en) * 2004-02-13 2011-11-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2008541746A (ja) * 2005-06-03 2008-11-27 ビオヴィトルム・アクチボラゲット（プブリクト） 新規プロセス
KR100670105B1 (ko) 2005-06-29 2007-01-17 주식회사 셀트리온 콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
DK2264060T3 (da) * 2006-01-26 2014-07-28 Recopharma Ab Sammensætninger og fremgangsmåder til inhibering af viral adhæsion
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US20080145893A1 (en) * 2006-09-17 2008-06-19 Excellegene Sa Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
AU2007317755A1 (en) * 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008069244A1 (ja) * 2006-12-05 2008-06-12 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
EP2511705A1 (en) * 2007-04-16 2012-10-17 Momenta Pharmaceuticals, Inc. Methods related to cell surface glycosylation
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
EP2188371B1 (en) * 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
PT4269578T (pt) 2008-03-06 2024-06-18 Halozyme Inc Produção em grande escala de hialuronidase solúvel
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
ES2517603T3 (es) * 2008-04-07 2014-11-03 Bayer Healthcare, Llc Procedimientos de producción recombinante de glucoproteínas
AU2009240637A1 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
CN103937797B (zh) 2008-09-15 2021-09-21 弗·哈夫曼-拉罗切有限公司 调节细胞摩尔渗透压浓度的组合物和方法
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
HUE035508T2 (en) 2009-11-17 2018-05-02 Squibb & Sons Llc Methods for enhanced protein production
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
CN102834111B (zh) * 2010-02-24 2014-11-12 齐姆内克斯公司 用于生产和纯化重组溶酶体α-甘露糖苷酶的方法
EP2610338A4 (en) 2010-08-02 2015-03-25 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCTION OF SUBSTANCE
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
RU2580020C2 (ru) 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CN102839157A (zh) * 2012-07-12 2012-12-26 扬州大学 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
NO2760138T3 (enExample) 2012-10-01 2018-08-04
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
CA2917484A1 (en) 2013-07-06 2015-01-15 Cadila Healthcare Limited Improved process for production of monoclonal antibodies
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT3110961T (pt) * 2014-02-27 2020-01-29 Hoffmann La Roche Modulação do crescimento celular e da glicosilação na produção de glicoproteínas recombinantes
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3152318A1 (en) * 2014-06-03 2017-04-12 Lupin Limited Cell culture process for producing a protein
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
ES2927271T3 (es) 2015-11-19 2022-11-03 Takeda Pharmaceuticals Co Inhibidor de esterasa C1 humana recombinante y usos del mismo
WO2017114900A1 (en) * 2015-12-29 2017-07-06 N.V. Nutricia Fermented formula with non-digestible oligosaccharides
WO2019106097A1 (en) * 2017-11-30 2019-06-06 F.Hoffmann-La Roche Ag Process for culturing mammalian cells
EP3880824B1 (en) 2018-11-13 2024-07-24 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20230152810A (ko) 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
KR20240167717A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 세포 배양 방법
WO2025219232A1 (en) 2024-04-15 2025-10-23 Evonik Operations Gmbh Application of small peptides supplemented cell culture media for improved cell performance

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
JPS5938488B2 (ja) 1979-05-07 1984-09-17 株式会社東芝 空気調和機
ATE55620T1 (de) * 1982-06-21 1990-09-15 Wellcome Found Verfahren zur herstellung von interferon.
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
JPH0639919B2 (ja) 1985-08-29 1994-05-25 トヨタ自動車株式会社 過給機付き内燃機関の異常判別装置
GB8606386D0 (en) * 1986-03-14 1986-04-23 Celltech Ltd Production of protein
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988001643A1 (en) 1986-08-29 1988-03-10 Endotronics, Inc. Method of culturing cells
JPH01257492A (ja) * 1987-03-05 1989-10-13 Green Cross Corp:The 異種蛋白質の生産増強方法
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US5151359A (en) * 1988-05-19 1992-09-29 Mitsui Toatsu Chemicals Incorporated Method for producing of human tissue type plasminogen activator
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
KR0132666B1 (en) * 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5096816A (en) * 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) * 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
JP3523293B2 (ja) † 1993-07-19 2004-04-26 住友製薬株式会社 インターフェロンの産生増強法
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP5515221B2 (ja) † 2008-01-28 2014-06-11 日油株式会社 ポリオキシエチレンソルビタン脂肪酸エステルの製造方法

Also Published As

Publication number Publication date
EP0832189B1 (en) 2005-08-17
HU226420B1 (en) 2008-12-29
MX9709452A (es) 1998-06-30
UA47428C2 (uk) 2002-07-15
ES2324046T5 (es) 2020-09-14
KR19990022473A (ko) 1999-03-25
CN1186514A (zh) 1998-07-01
ES2324046T3 (es) 2009-07-29
PL185484B1 (pl) 2003-05-30
CA2220684C (en) 2002-11-12
EP1609853B2 (en) 2020-01-22
NO322276B1 (no) 2006-09-04
PL323737A1 (en) 1998-04-14
JP4348376B2 (ja) 2009-10-21
BR9609150A (pt) 1999-02-23
DE69635076D1 (de) 2005-09-22
ZA964776B (en) 1997-12-08
SI0832189T1 (sl) 2006-02-28
US5705364A (en) 1998-01-06
NO975674D0 (no) 1997-12-05
KR100496356B1 (ko) 2005-11-25
DE69635076T3 (de) 2009-01-15
BG102101A (en) 1998-07-31
IS4626A (is) 1997-12-03
ES2248812T5 (es) 2008-12-16
HK1017903A1 (en) 1999-12-03
SI0832189T2 (sl) 2008-12-31
EP0832189B2 (en) 2008-07-09
CZ293719B6 (cs) 2004-07-14
AU6095296A (en) 1996-12-24
AR011439A2 (es) 2000-08-16
RO120267B1 (ro) 2005-11-30
NO975674L (no) 1998-02-06
SI1609853T2 (sl) 2020-07-31
ATE425245T2 (de) 2009-03-15
SK167097A3 (en) 1998-07-08
TW426734B (en) 2001-03-21
SI1609853T1 (sl) 2009-08-31
DE69637867D1 (de) 2009-04-23
CN1166772C (zh) 2004-09-15
PT1609853E (pt) 2009-06-09
JPH11507523A (ja) 1999-07-06
WO1996039488A1 (en) 1996-12-12
IL122398A0 (en) 1998-06-15
NZ310202A (en) 1999-10-28
EP1609853B1 (en) 2009-03-11
DK1609853T3 (da) 2009-06-02
BG63213B1 (bg) 2001-06-29
HUP9900920A3 (en) 2001-06-28
TR199701543T1 (xx) 1998-05-21
SA96170351B1 (ar) 2006-07-04
AU717847B2 (en) 2000-04-06
IL122398A (en) 2001-12-23
OA10753A (en) 2002-12-11
GEP20012519B (en) 2001-08-27
ATE302266T1 (de) 2005-09-15
JP2007190024A (ja) 2007-08-02
EA199700364A1 (ru) 1998-04-30
DE69635076T2 (de) 2006-06-01
EP0832189A1 (en) 1998-04-01
EP1609853A1 (en) 2005-12-28
AR004940A1 (es) 1999-04-07
IS2614B (is) 2010-04-15
EA001215B1 (ru) 2000-12-25
SK282658B6 (sk) 2002-11-06
HK1087151A1 (en) 2006-10-06
ES2248812T3 (es) 2006-03-16
MY113496A (en) 2002-03-30
CA2220684A1 (en) 1996-12-12
HUP9900920A2 (hu) 1999-07-28
TW516962B (en) 2003-01-11
DK0832189T3 (da) 2005-11-21
DK0832189T4 (da) 2008-10-27
CZ390997A3 (cs) 1998-06-17

Similar Documents

Publication Publication Date Title
DK1609853T4 (da) Fremgangsmåde til kontrol med sialylering af proteiner produceret af pattedyrscellekultur
DK0866876T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner i E.coli ved hjælp af fermentering i høje celletætheder
FI950042L (fi) Menetelmä entsyymin immobilisoimiseksi mikrobisolun soluseinämään valmistamalla fuusioproteiini
DK0408029T3 (da) Fremgangsmåde til fraktionering af plasmaprotein
DK0807166T3 (da) Metode til forberedelse af en udifferentieret celle
DE69636831D1 (de) Verfahren zur herstellung heteromultimerer polypeptide
ATE174578T1 (de) Neues verfahren zur biologischen abbausteuerung
DK0877090T3 (da) Fremgangsmåde til produktion af L-aminosyrer
DK0770687T3 (da) Fremgangsmåde til fremstilling af nicotinsyreamid
DK0789767T3 (da) Fremgangsmåde til fremstilling af oprensede papilomavirusproteiner
FI921059A7 (fi) Menetelmä hyötyproteiinien erittämiseksi hiivoista
DK0977873T3 (da) Fremgangsmåde til spaltning af fusionsproteiner
FI922409A7 (fi) Menetelmä soluviljelyä varten
DK0763100T3 (da) Fremgangsmåde til rensning af Clostridium difficile-texin og fremstilling af monospecifkke antistoffer
ZA967833B (en) Method and composition for treating mammalian diseases caused by inflammatory response
EP0851027A4 (en) METHOD FOR CONTROLLING THE BREEDING OF LACTIC ACID BACTERIA
DK112589D0 (da) Fremgangsmaade til fremstilling af l-alpha-aminosyrer
DK0658626T3 (da) Fremgangsmåder til produktion af protein C
DK93793A (da) Fremgangsmåde til fremstilling af naturlige mælkeproteiner
DK0785281T3 (da) Fremgangsmåde til genetisk differentiering af humlesort
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner
DK526889D0 (da) Apparat til gennemfoerelse af membranskilleprocesser
DK23592D0 (da) Metode til selvreguleret kontrol af vaekstpotential for maligne celler
KR900007299A (ko) 고농도배양에 의한 단세포단백질의 제조방법
US5807733A (en) Mammalian prostaglandin H synthase-2 fusion proteins